Report : North America Sepsis Diagnostics Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – by Product (Instruments, Reagents and Assays, Blood Culture Media, and Software), Technology [Molecular Diagnostics (Polymerase Chain Reaction, Peptide Nucleic Acid-Fluorescent in Situ Hybridization, Syndromic Panel-Based Testing, and Microarrays), Flow Cytometry, Microfluidics, Immunoassay, Biomarkers, and Microbiology], Method (Automated Diagnostics and Conventional Diagnostics), Test Type (Point-of-Care Tests and Laboratory Tests), Pathogen (Bacterial Sepsis, Fungal Sepsis, and Others), and End User (Hospitals, Pathology and Reference Laboratories, and Others)
At 9.1% CAGR, the North America Sepsis Diagnostics Market is speculated to be worth US$ 513.33 million by 2028, says Business Market Insights
According to Business Market Insights’ research, the North America sepsis diagnostics market was valued at US$ 279.06 million in 2021 and is expected to reach US$ 513.33 million by 2028, registering a CAGR of 9.1% from 2021 to 2028. High incidence of sepsis due to increasing nosocomial infections are the critical factors attributed to the North America sepsis diagnostics market expansion.
Infection is the root cause of sepsis. Sepsis mainly occurs in immunocompromised people, such as those taking chemotherapy, having a splenectomy, and suffering from AIDS and chronic illnesses like diabetes. Among several types of infections, nosocomial infections are the primary cause of morbidity and mortality among hospitalized patients. For instance, according to the "2020 National and State Healthcare-Associated Infections Progress Report", published by the Centers for Disease Control and Prevention (CDC) in 2021, about 24%, 35%, and 15% increase was recorded in central line-associated bloodstream infections, ventilator-associated events, and Methicillin-resistant Staphylococcus Aureus (MRSA) bacteremia, respectively, between 2019 and 2020 in the US. Thus, the rising bloodstream infections will increase the adoption of sepsis diagnostic products. Most deaths can be prevented through early diagnosis and appropriate clinical management. These deaths are often a consequence of diarrheal diseases or lower respiratory infections. Thus, the high incidence rate of sepsis is expected to boost the demand for sepsis diagnostic products, thereby supporting the North America sepsis diagnostics market growth during the forecast period.
On the contrary, lack of skilled professionals hampers the North America sepsis diagnostics market.
Based on product, the North America sepsis diagnostics market is segmented into instruments, reagents and assays, blood culture media, and software. The blood culture media segment held 43.2% share of North America sepsis diagnostics market in 2021, amassing US$ 120.54 million. It is projected to garner US$ 220.09 million by 2028 to expand at 9.0% CAGR during 2021–2028.
Based on technology, the North America sepsis diagnostics market is segmented into molecular diagnostics, flow cytometry, microfluidics, immunoassay, biomarkers, and microbiology. The microbiology segment held 44.2% share of North America sepsis diagnostics market in 2021, amassing US$ 123.32 million. It is projected to garner US$ 222.64 million by 2028 to expand at 8.8% CAGR during 2021–2028.
Based on method, the North America sepsis diagnostics market is segmented into automated diagnostics and conventional diagnostics. The conventional diagnostics segment held 66.0% share of North America sepsis diagnostics market in 2021, amassing US$ 184.07 million. It is projected to garner US$ 333.71 million by 2028 to expand at 8.9% CAGR during 2021–2028.
Based on test type, the North America sepsis diagnostics market is segmented into point-of-care tests and laboratory tests. The laboratory tests segment held 83.8% share of North America sepsis diagnostics market in 2021, amassing US$ 233.97 million. It is projected to garner US$ 428.51 million by 2028 to expand at 9.0% CAGR during 2021–2028.
Based on pathogen, the North America sepsis diagnostics market is segmented into bacterial sepsis, fungal sepsis, and others. The bacterial sepsis segment held 79.6% share of North America sepsis diagnostics market in 2021, amassing US$ 222.22 million. It is projected to garner US$ 414.70 million by 2028 to expand at 9.3% CAGR during 2021–2028.
Based on end user, the North America sepsis diagnostics market is segmented into hospitals, pathology and reference laboratories, and others. The hospitals segment held 47.3% share of North America sepsis diagnostics market in 2021, amassing US$ 132.01 million. It is projected to garner US$ 244.61 million by 2028 to expand at 9.2% CAGR during 2021–2028.
Based on country, the North America sepsis diagnostics market has been categorized into the US, Canada, and Mexico. Our regional analysis states that the US captured 82.3% share of North America sepsis diagnostics market in 2021. It was assessed at US$ 229.79 million in 2021 and is likely to hit US$ 424.35 million by 2028, exhibiting a CAGR of 9.2% during the forecast period.
Key players dominating the North America sepsis diagnostics market are Abbott; BD; bioMerieux SA; Danaher (Beckman Coulter); F. HOFFMANN-LA ROCHE LTD.; Immunexpress Inc.; Luminex Corporation; T2 Biosystems, Inc.; and THERMO FISHER SCIENTIFIC INC., among others.
- In Feb 2022; Abbott recalled several powdered infant formula products following reports of four infants developing bacterial infections after consuming the products. Three Cronobacter sakazakii infections and one Salmonella Newport infection was found among four infants in three states, namely, Minnesota, Ohio, and Texas. Cronobacter bacteria can cause severe, life-threatening infections (sepsis) or meningitis.
Contact Us
Contact Person: Sameer Joshi
Phone: +1- 646- 491- 9876
Email id: sam@businessmarketinsights.com